Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02677896 · ClinicalTrials.gov registry record · Phase 3
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
A Phase 3 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,150
- Enrollment target
NCT02677896 is a Phase 3 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 1,150 participants.
The verdict
NCT02677896, a Phase 3 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,150 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by radiographic progression-free survival (rPFS) based on central review. The study also evaluated the safety of enzalutamide plus ADT in mHSPC.
Interventions
- DRUG Placebo
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,150 participants |
| Start Date | 2016-03-09 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02677896
The ClinicalTrials.gov registry entry for NCT02677896 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02677896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02677896 about?
NCT02677896 is a clinical study titled "A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)". The purpose of this study was to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by radiographic progression-free survival (rPFS) based on central review. The study also evaluated the safety of enzalutamide plus ADT in mHSPC.
What is the current status of trial NCT02677896?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,150 participants. The study started on 2016-03-09. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT02677896?
The interventions under investigation include: Placebo (DRUG), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02677896?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.